BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

DualityBio, BioNTech Expand Partnership for Solid Tumor Antibody-Drug Conjugate

The agreement further builds upon the strategic collaboration the companies announced in April 2023. Under the terms of the agreements, DualityBio will re...

August 08, 2023 | News

Gracell Biotechnologies Secures Up to $150M in Private Placement with Premier Healthcare Investors

$100 million financing upfront with up to an additional $50 million tied to exercise of warrants Aggregate financing expected to extend c...

August 08, 2023 | News

Proteintech Accelerates Growth with Expansions in the US and China

Proteintech, the benchmark in antibodies and life science solutions, recently expanded at its US headquarters in Rosemont, IL, opened up a new office in Sh...

August 07, 2023 | News

VenusP-Valve Receives IDE Approval, Launching New Era in Chinese Valve Solutions

IDE refers to the exemption of medical devices intended for marketing from regulatory requirements, allowing clinical trials to be conducted on such device...

August 07, 2023 | News

Ascentage Pharma Gets FDA Clearance for Global Phase III Trial of Lisaftoclax in CLL/SLL Patients

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...

August 07, 2023 | News

JinMed's Nanobathing Products Earn Patents, Secure Procurement Deal with Shanghai Zhongjin HongKang Medical Technology

Currently, the Company's nanobathing products have been granted an invention patent and four utility model patents. Among them, one medical nanobathing car...

August 04, 2023 | News

US FDA Grants Orphan Drug Status to ABM-1310 for BRAF V600 Glioblastoma

Orphan Drug Designation is a significant recognition bestowed by the FDA to the drugs used in the treatment of rare diseases. This designation intends to e...

August 03, 2023 | News

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

Chinese Patent Granted for CytoMed Therapeutics' Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its propr...

August 02, 2023 | News

Indonesia-China Healthcare and Biotech Investment Forum Explores Collaborative Opportunities

The forum was chaired by Mr. Jafar WANG, Co-Chief Investment Officer of Legend Capital, who mentioned Legend Capital's latest "Ecosystem plus" strategy in ...

August 01, 2023 | News

NMPA and FDA Approve First-in-Human Trial for LBL-034 in Multiple Myeloma

This is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion clinical study, and plans to enroll patients with relapsed/ref...

August 01, 2023 | News

Daewoong Pharmaceutical Seeks Approval for Fexuprazan in China's Anti-Ulcer Drug Market

Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for the treatment of gastroesophageal reflux disease (GERD), ...

July 31, 2023 | News

Transcenta's Anti-sclerostin Antibody TST002 Approved for Phase II Trial in China for Reduced Bone Density Patients

This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...

July 31, 2023 | News

Recbio's Novel Adjuvanted Shingles Vaccine Receives Clinical Trial Approval in China and Progresses Overseas

The Company proposes to adopt a randomized, double-blind, Shingrix® parallel controlled phase I clinical trial in 180 healthy adult subjects aged 40 an...

July 27, 2023 | News

Stay Connected